EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudieOpen Access · CC BY 4.0

Methoxyflurane Instead of Morphine in Acute Coronary Syndrome Patients: Results of the Randomized Controlled METHANE-SIRIO 4 Study

Piotr Niezgoda iD, Przemysław Podhajski, Michał Kasprzak, Malwina Barańska, Oscar Rakotoarison, Bożena Karolko, Łukasz Pietrzykowski, Piotr Michalski, Agata Kosobucka, Adam Sikora, Joanna Chałupka, Michał Marszałł und 3 weitere

Thrombosis and Haemostasis · 01.08.2026 · 126 (08) · 822-831

DOI: 10.1055/a-2698-3958 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.08.2026. Verfasst von Piotr Niezgoda und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology and Internal Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland. Hauptthemen laut MEDLINE: Morphine, Acute Coronary Syndrome, Platelet Aggregation Inhibitors, Adenosine. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nicolaus Copernicus University in Toruń.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Morphine is known to negatively influence the pharmacokinetics (PK) and the antiplatelet effect of oral P2Y12 receptor inhibitors administered due to an acute coronary syndrome. Worldwide studies of the potential approaches to overcome the undesired morphine effect have been only partially successful. The aim of the METHANE-SIRIO 4 study was to evaluate the PK and pharmacodynamics of ticagrelor and its active metabolite in unstable angina (UA) patients treated with morphine or methoxyflurane. Consecutive patients diagnosed with UA, randomized into the study arms, underwent the assessment of platelet reactivity using the Multiplate analyzer at nine predefined study time points. Serum concentrations of ticagrelor and its active metabolite, AR-C124910XX, were measured for each study participant. Median platelet reactivity was significantly lower in patients who received ticagrelor and methoxyflurane versus ticagrelor alone at 30 minutes postticagrelor loading dose. A trend toward lower reactivity was observed at 45 and 240 minutes. Significant differences in median serum concentrations of ticagrelor and its active metabolite were most pronounced between patients treated with ticagrelor and methoxyflurane versus ticagrelor and morphine. Co-administration of methoxyflurane in acute coronary syndrome patients allows for the avoidance of negative effects of morphine and has the additional effect of inhibiting platelet reactivity. Further randomized studies would be recommended to support these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MorphineAcute Coronary SyndromePlatelet Aggregation InhibitorsAdenosinePurinergic P2Y Receptor AntagonistsAngina, UnstableAnesthetics, InhalationHumansTicagrelorFemaleMaleMiddle AgedAgedDrug InteractionsTreatment OutcomePlatelet Function TestsBlood PlateletsPlatelet AggregationTime Factors

Substanzen

MorphineTicagrelorPlatelet Aggregation InhibitorsAdenosinePurinergic P2Y Receptor AntagonistsAR C124910XXAnesthetics, Inhalation

Autor:innen und Institutionen

  • Department of Cardiology and Internal Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland.
  • Institute for Heart Diseases, Wroclaw Medical University, Wroclaw, Poland.
  • Department of Health Promotion, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland.
  • The Department of Medicinal Chemistry, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland.
  • Department of Pharmaceutical Technology, Faculty of Pharmacy, Medical Biotechnology and Laboratory Medicine, Pomeranian Medical University, Szczecin, Poland.

ORCID-Profile: Piotr Niezgoda, Wiktor Kuliczkowski

Förderung

  • Nicolaus Copernicus University in Toruń

Zitieren

APA

Niezgoda, P., Podhajski, P., Kasprzak, M., Barańska, M., Rakotoarison, O., Karolko, B., Pietrzykowski, Ł., Michalski, P., Kosobucka, A., Sikora, A., Chałupka, J., Marszałł, M., Kuliczkowski, W., Kubica, A., & Kubica, J. (2026). Methoxyflurane Instead of Morphine in Acute Coronary Syndrome Patients: Results of the Randomized Controlled METHANE-SIRIO 4 Study. Thrombosis and Haemostasis, 126(08), 822-831. https://doi.org/10.1055/a-2698-3958

Vancouver

Niezgoda P, Podhajski P, Kasprzak M, Barańska M, Rakotoarison O, Karolko B, et al. Methoxyflurane Instead of Morphine in Acute Coronary Syndrome Patients: Results of the Randomized Controlled METHANE-SIRIO 4 Study. Thrombosis and Haemostasis. 2026;126(08):822-831. doi:10.1055/a-2698-3958

BibTeX
@article{Niezgoda2026,
  author = {Niezgoda, Piotr and Podhajski, Przemysław and Kasprzak, Michał and Barańska, Malwina and Rakotoarison, Oscar and Karolko, Bożena and Pietrzykowski, Łukasz and Michalski, Piotr and Kosobucka, Agata and Sikora, Adam and Chałupka, Joanna and Marszałł, Michał and Kuliczkowski, Wiktor and Kubica, Aldona and Kubica, Jacek},
  title = {Methoxyflurane Instead of Morphine in Acute Coronary Syndrome Patients: Results of the Randomized Controlled METHANE-SIRIO 4 Study},
  journal = {Thrombosis and Haemostasis},
  year = {2026},
  volume = {126},
  number = {08},
  pages = {822--831},
  doi = {10.1055/a-2698-3958}
}
Kostenlos starten →